<DOC>
	<DOCNO>NCT00805350</DOCNO>
	<brief_summary>Primary objective : - To assess efficacy eplivanserin 5mg/day comparison placebo 6 week treatment sleep maintenance insomniac patient , measure Polysomnography Wake Time After Sleep Onset ( PSG-WASO ) Polysomnography Number Awakenings ( PSG-NAW ) . Secondary objective : - To evaluate effect eplivanserin 5mg/day compare placebo 6 week treatment sleep parameter measure PSG recording ( Total Sleep Time - PSG-TST , Sleep Efficiency - PSG-SE , Latency Persistent Sleep - PSG-LPS ) report patient ( Wake Time After Sleep Onset - pr-WASO , Number Awakenings - pr-NAW , Total Sleep Time - pr-TST , Quality Sleep - QoS Refreshing Quality Sleep - RqoS ) . - To evaluate effect eplivanserin 5mg/day sleep architecture compare placebo . - To evaluate effect eplivanserin 5mg/day daytime function use Sleep Impact Scale ( SIS ) , compare placebo 6 week treatment . - To evaluate patient 's impression treatment effect use Patient 's Global Impression questionnaire . - To evaluate potential next-day residual effect ( use patient 's morning questionnaire psychometric test ) eplivanserin 5mg/day compare placebo . - To evaluate potential rebound insomnia follow abrupt discontinuation eplivanserin 5mg/day comparison placebo . - To evaluate effect eplivanserin , compare placebo , quality life patient primary insomnia use SF-36 Health Survey . - To evaluate clinical safety tolerability eplivanserin 5mg/day compare placebo .</brief_summary>
	<brief_title>Efficacy Safety Eplivanserin 5mg/Day Insomnia Characterized Sleep Maintenance Difficulties</brief_title>
	<detailed_description>Randomized , double-blind , placebo , control study 2 parallel group Duration treatment : 6 week Duration observation : 9 week</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>SR 46349B</mesh_term>
	<criteria>Diagnosis primary insomnia base DSMIVTR ( Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revisions ) criterion Inpatients . Mean screen PSGWASO screen night 1+ screen night 2 &lt; 45 mn , screen night PSGWASO &lt; 30 mn . Mean screen PSGTST screen night 1 + screen night 2 ≥7 hour ≤3hours . Mean screen PSGLPS screen night 1+ screen night 2 &gt; 30 mn . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Insomnia</keyword>
	<keyword>Sleep Maintenance</keyword>
	<keyword>Polysomnography</keyword>
</DOC>